Financial News
All
Basic Materials
Communication Services
Consumer Cyclical
Consumer Defensive
Energy
Financial Services
Healthcare
Industrials
Real Estate
Technology
Utilities
Macro
All Sentiment
Bullish
Neutral
Bearish
3,819 articles
📰
What Investors Should Know About a $24 Million Exit From a Medical Device Stock Down 9% This Past Year
This medical technology firm delivers integrated blood management solutions to healthcare providers and plasma centers worldwide.
📰
HYTN Appoints Fabian Monaco to Board of Directors
VANCOUVER, British Columbia, March 20, 2026 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE:HYTN, FSE: 85W0, OTC:HYTNF) ("HYTN" or the "Company"), a...
📰
HYTN Appoints Fabian Monaco to Board of Directors
VANCOUVER, British Columbia, March 20, 2026 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE:HYTN, FSE: 85W0, OTC:HYTNF) ("HYTN" or the "Company"), a...
📰
Publication relating to transparency notifications
REGULATED INFORMATION
Publication relating to transparency notifications
Mont-Saint-Guibert (Belgium), March 20, 2026, 10:30 pm CET / 5:30 pm ET – In...
📰
Does This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6?
Organon & Co. develops branded and biosimilar therapies with a focus on women’s health and specialty pharmaceuticals.
12 Consumer Discretionary Stocks Moving In Friday's After-Market Session
Gainers
Chegg (NYSE:CHGG) stock rose 21.7% to $0.55 during Friday's after-market session. The market value of their outstanding shares is at...
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers
Firefly Neuroscience (NASDAQ:AIFF) stock rose 25.5% to $1.92 during Friday's after-market session. The company's market cap stands...
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers
Firefly Neuroscience (NASDAQ:AIFF) stock rose 25.5% to $1.92 during Friday's after-market session. The company's market cap stands...
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers
Firefly Neuroscience (NASDAQ:AIFF) stock rose 25.5% to $1.92 during Friday's after-market session. The company's market cap stands...
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers
Firefly Neuroscience (NASDAQ:AIFF) stock rose 25.5% to $1.92 during Friday's after-market session. The company's market cap stands...
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers
Firefly Neuroscience (NASDAQ:AIFF) stock rose 25.5% to $1.92 during Friday's after-market session. The company's market cap stands...
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers
Firefly Neuroscience (NASDAQ:AIFF) stock rose 25.5% to $1.92 during Friday's after-market session. The company's market cap stands...
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers
Firefly Neuroscience (NASDAQ:AIFF) stock rose 25.5% to $1.92 during Friday's after-market session. The company's market cap stands...
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers
Firefly Neuroscience (NASDAQ:AIFF) stock rose 25.5% to $1.92 during Friday's after-market session. The company's market cap stands...
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers
Firefly Neuroscience (NASDAQ:AIFF) stock rose 25.5% to $1.92 during Friday's after-market session. The company's market cap stands...
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers
Firefly Neuroscience (NASDAQ:AIFF) stock rose 25.5% to $1.92 during Friday's after-market session. The company's market cap stands...
📰
Halper Sadeh LLC is Investigating Whether EHAB, JHG, COUR are Obtaining Fair Deals for their Shareholders
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
The proposed transactions may contain terms...
📰
Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, March 20, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on...
ASML's AI Boom Comes With Friction
Layoffs used to be a sign that the company was not doing well. Perhaps management misjudged a business cycle, a new technology hurt margins, or a...
📰
AIxCrypto Announces Fourth Quarter 2025 Earnings Release Date and Conference Call Details
LOS ANGELES, March 20, 2026 /PRNewswire/ -- AIxCrypto Holdings, Inc. ("AIxC" or the "Company"), a U.S.-Nasdaq listed company dedicated to building an...
📰
argenx announces Annual General Meeting of Shareholders on May 6, 2026
March 20, 2026
Amsterdam, the Netherlands – argenx SE ((Euronext &amp, NASDAQ:ARGX), a global immunology company committed to improving the lives...
📰
This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund
RTW Investments loads up on iRhythm Holdings with 1.18M Shares Worth $210 million. iRhythm delivers wearable cardiac monitoring and analytics...
LLY's Next-Gen Obesity Drug Meets Goal in First Phase III Study for T2D
Eli Lilly reports strong Phase III results for retatrutide in type 2 diabetes, with significant A1C reduction and up to 16.8% weight loss in the...
LLY's Next-Gen Obesity Drug Meets Goal in First Phase III Study for T2D
Eli Lilly reports strong Phase III results for retatrutide in type 2 diabetes, with significant A1C reduction and up to 16.8% weight loss in the...
LLY's Next-Gen Obesity Drug Meets Goal in First Phase III Study for T2D
Eli Lilly reports strong Phase III results for retatrutide in type 2 diabetes, with significant A1C reduction and up to 16.8% weight loss in the...
LLY's Next-Gen Obesity Drug Meets Goal in First Phase III Study for T2D
Eli Lilly reports strong Phase III results for retatrutide in type 2 diabetes, with significant A1C reduction and up to 16.8% weight loss in the...
Novartis Strikes $3B Oncology Deal for Breast Cancer Asset
NVS bets $2B upfront on SNV4818 to expand precision oncology in breast cancer, targeting a large mutation-driven market and boosting long-term...
Novartis Strikes $3B Oncology Deal for Breast Cancer Asset
NVS bets $2B upfront on SNV4818 to expand precision oncology in breast cancer, targeting a large mutation-driven market and boosting long-term...
Novartis Strikes $3B Oncology Deal for Breast Cancer Asset
NVS bets $2B upfront on SNV4818 to expand precision oncology in breast cancer, targeting a large mutation-driven market and boosting long-term...
Novartis Strikes $3B Oncology Deal for Breast Cancer Asset
NVS bets $2B upfront on SNV4818 to expand precision oncology in breast cancer, targeting a large mutation-driven market and boosting long-term...
Will the Recent Label Expansion of BMY's Sotyktu Boost Its Prospects?
BMY's Sotyktu PsA approval boosts its immunology push, expands market reach, and sharpens its competitive stance amid pressure from legacy drug...
Will the Recent Label Expansion of BMY's Sotyktu Boost Its Prospects?
BMY's Sotyktu PsA approval boosts its immunology push, expands market reach, and sharpens its competitive stance amid pressure from legacy drug...
Will the Recent Label Expansion of BMY's Sotyktu Boost Its Prospects?
BMY's Sotyktu PsA approval boosts its immunology push, expands market reach, and sharpens its competitive stance amid pressure from legacy drug...
📰
Halper Sadeh LLC is Investigating Whether SEM, FONR, NWE are Obtaining Fair Deals for their Shareholders
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
The proposed transactions may contain terms...
📰
Halper Sadeh LLC is Investigating Whether SEM, FONR, NWE are Obtaining Fair Deals for their Shareholders
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
The proposed transactions may contain terms...
Theravance's Q4 Earnings and Revenues Miss Estimates
TBPH's posts Q4 earnings miss despite 145% revenue surge; scraps Ampreloxetine, launches restructuring and weighs a potential sale.
Theravance's Q4 Earnings and Revenues Miss Estimates
TBPH's posts Q4 earnings miss despite 145% revenue surge; scraps Ampreloxetine, launches restructuring and weighs a potential sale.
Theravance's Q4 Earnings and Revenues Miss Estimates
TBPH's posts Q4 earnings miss despite 145% revenue surge; scraps Ampreloxetine, launches restructuring and weighs a potential sale.